ReviewJournal of the Endocrine Society2026
Disuse Bone Loss After Spinal Cord Injury: Scope and Challenges, Potential Mechanisms, Treatment, and Future Directions.
Review in Journal of the Endocrine Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mechanical Unloading Inhibits Osteoblast Differentiation via Downregulation of OGT-Mediated O-GlcNAcylation.Current issues in molecular biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Traumatic spinal cord injury (SCI) is a major insult that causes motor and sensory neurological deficits and multisystem dysfunction. The skeletal system is severely affected after SCI, with disuse bone loss being one of the most common and challenging complications. Changes in bone mass and structure after SCI are progressive and involve both trabecular and cortical components of the long bones below the lesion. The weight-bearing trabecular regions of the distal femur and proximal tibia are the most compromised sites with the highest incidence of fracture. Furthermore, SCI-associated bone loss is resistant to currently available pharmacologic and rehabilitative treatment, especially during the chronic phase after injury. Therefore, there is a need to highlight the scale of this clinical problem in the SCI patient population and address the challenges. Protection against bone loss during the early phases and restoration of bone structure in the later or chronic phases of SCI are necessary to reduce the risk of fracture and avoid the associated morbidities and mortalities and allow safe use of walking aids and exoskeletal ReWalk devices. Identifying the potential mechanisms underlying SCI-induced bone loss is critical so that new and more effective therapeutic strategies can be developed. The goal of this review is to provide an up-to-date overview of SCI bone loss and discuss challenges, potential mechanisms, and progress in pharmacological treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.